Aadi Bioscience Inc Stock Price, News & Analysis

Welcome to our dedicated page for Aadi Bioscience news (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.

Aadi Bioscience, Inc. (Nasdaq: AADI) is a precision oncology company whose news flow reflects both commercial-stage activity and a significant strategic transformation. Company press releases describe Aadi as focused on applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers.

News coverage for AADI has included financial results and earnings updates, such as quarterly reports highlighting FYARRO® product sales and operating performance. Investors can also find announcements about upcoming webcasts where Aadi discusses quarterly and full-year results and provides corporate updates.

A key theme in recent Aadi news has been its business transformation. The company has reported a strategic plan involving the sale of its FYARRO business and associated infrastructure to KAKEN Pharmaceutical, the in-licensing of a three-asset, preclinical antibody-drug conjugate (ADC) portfolio from WuXi Biologics and HANGZHOU DAC, and a PIPE financing. Related news items include the filing of a definitive proxy statement, the scheduling and outcome of a Special Meeting of Stockholders, and the closing of the PIPE financing.

Additional AADI news highlights pipeline and clinical developments, such as updates on the PRECISION1 tumor-agnostic trial of nab-sirolimus and decisions to halt or adjust trials based on data and strategic priorities. The company also issues releases on leadership and governance changes, including the appointment of a Chief Scientific Officer with extensive ADC experience and the addition of board members with backgrounds in ADC development.

For investors and followers of oncology therapeutics, the AADI news stream provides insight into how the company is shifting from FYARRO commercialization toward an in-licensed ADC portfolio, while managing capital through private placements and strategic transactions. Regular news items offer context on Aadi’s evolving pipeline, financing activities, and corporate direction.